GENI Stock Overview
Develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GENinCode Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.038 |
| 52 Week High | UK£0.10 |
| 52 Week Low | UK£0.033 |
| Beta | 0.75 |
| 11 Month Change | -8.43% |
| 3 Month Change | -43.70% |
| 1 Year Change | -32.14% |
| 33 Year Change | -89.44% |
| 5 Year Change | n/a |
| Change since IPO | -91.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENI | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -10.6% | 2.9% | 0.7% |
| 1Y | -32.1% | -19.3% | 8.7% |
Return vs Industry: GENI underperformed the UK Healthcare industry which returned -19.3% over the past year.
Return vs Market: GENI underperformed the UK Market which returned 8.7% over the past year.
Price Volatility
| GENI volatility | |
|---|---|
| GENI Average Weekly Movement | 7.2% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GENI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: GENI's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 42 | Matthew Walls | www.genincode.com |
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company’s molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.
GENinCode Plc Fundamentals Summary
| GENI fundamental statistics | |
|---|---|
| Market cap | UK£6.72m |
| Earnings (TTM) | -UK£5.94m |
| Revenue (TTM) | UK£2.60m |
2.6x
P/S Ratio-1.1x
P/E RatioIs GENI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENI income statement (TTM) | |
|---|---|
| Revenue | UK£2.60m |
| Cost of Revenue | UK£1.31m |
| Gross Profit | UK£1.29m |
| Other Expenses | UK£7.23m |
| Earnings | -UK£5.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 49.44% |
| Net Profit Margin | -228.70% |
| Debt/Equity Ratio | 0% |
How did GENI perform over the long term?
See historical performance and comparison